BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.26.0//EN
X-ORIGINAL-URL:https://steven-kantor.com/
X-WR-CALNAME:Steven A Kantor
X-WR-CALDESC:
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-0da474fc8e382f9c6d6d774bb433339a@steven-kantor.com
DTSTART;TZID=America/New_York:20260825T080000
DTEND;TZID=America/New_York:20260827T180000
DTSTAMP:20260827T081545Z
CREATED:20260827
LAST-MODIFIED:20260827
PRIORITY:5
SEQUENCE:2
TRANSP:OPAQUE
SUMMARY:Life Sciences Collaborative Boston Welcomes Yotam Eldar, MD, Founder & CEO of Modulight Biotherapeutics
DESCRIPTION:\n\n\n\n\n\n\n\n\nThe Life Sciences Collaborative – Boston Chapter held its monthly meeting on August 25, 2026, at Cushman & Wakefield in Boston, bringing together members of the region’s life sciences community for an engaging discussion on biotechnology, entrepreneurship, and the realities of building an emerging life sciences company.\nOur featured speaker was Yotam Eldar, MD, Founder and CEO of Modulight Biotherapeutics.\nFrom Neurology to Biotech Entrepreneurship\nYotam shared his professional journey from neurology to biotech entrepreneurship, offering members a firsthand perspective on what it takes to move from a medical career into building and leading an emerging biotechnology company.\nThe discussion provided valuable insight into the opportunities and challenges founders encounter as they work to transform innovative ideas into companies with the potential to reach patients.\nNavigating the Path to Commercialization\nA significant part of the conversation focused on what comes next for Modulight Biotherapeutics.\nLike many emerging biotechnology companies, Modulight must navigate several important stages on the path toward commercialization, including raising capital, conducting clinical trials, pursuing regulatory approval, and ultimately bringing its technology to market.\nThe discussion highlighted an important reality of life sciences entrepreneurship: promising innovation is only the beginning. Building a successful biotech company also requires capital, regulatory strategy, clinical development, strong leadership, and the ability to navigate a long and complex commercialization process.\nSupporting Boston’s Life Sciences Community\nThese conversations are an important part of what makes the Life Sciences Collaborative Boston Chapter such a valuable community.\nBy bringing together biotech founders, investors, executives, and advisors, the group creates opportunities to exchange experiences, discuss real-world challenges, and build relationships with people who understand what it takes to develop and grow life sciences companies.\nThank you to Yotam Eldar, MD, for sharing his experience and insights with our members, and to Cushman & Wakefield for hosting our August meeting.\nWe look forward to continuing to connect the founders, investors, executives, and advisors helping shape the future of Boston’s life sciences and biotechnology ecosystem.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
URL:https://steven-kantor.com/events/life-sciences-collaborative-boston-welcomes-yotam-eldar-md-founder-ceo-of-modulight-biotherapeutics/
CATEGORIES:LSC - Boston
ATTACH;FMTTYPE=image/jpeg:https://steven-kantor.com/wp-content/uploads/2026/08/IMG_0085-scaled-e1787784886820.jpeg
END:VEVENT
END:VCALENDAR